Biocon Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of Re. 0.50 per share. Key corporate actions include the full integration of Biocon Biologics Limited (BBL) as a wholly-owned subsidiary, the adoption of a new Long-Term Incentive Plan, and significant leadership changes, including a change in Statutory Auditors and key board appointments to support the new organizational structure.
Financial Highlights
For the financial year ended March 31, 2026, Biocon Limited reported standalone revenue from operations of Rs. 23,464 million and a net profit of Rs. 372 million. On a consolidated basis, the company achieved revenue of Rs. 1,69,270 million, with a net profit attributable to shareholders of Rs. 3,856 million for the same period. The Board has recommended a final dividend of 10% (Re. 0.50 per equity share), with a record date set for Friday, July 03, 2026.
Strategic Integration of Biocon Biologics
A core focus of the recent Board meeting was the full integration of Biocon Biologics Limited (BBL) to create a Unified Global Biopharmaceutical Leader. The company has approved the acquisition of the remaining ~2% stake in BBL held by employees and other shareholders. This transaction involves a share swap through the issuance of up to 87,92,317 equity shares of Biocon Limited, valued at Rs. 376.16 per share.
Leadership and Governance Updates
The company announced significant leadership transitions. M/s. S. R. Batliboi & Associates LLP has been recommended as the new Statutory Auditor for a five-year term, succeeding M/s. B S R & Co. LLP. In terms of senior management, Dr. Anuj Goel has been designated as Chief Development Officer, and Mr. Susheel Umesh as Chief Commercial Officer – Emerging Markets and Head of Global API & Global BD.
Furthermore, to support the unified corporate structure, the Board has recommended several new appointments to the Board of Directors effective August 01, 2026, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai as Independent Directors.
Future Incentives and AGM
The Board has approved the Biocon Unity Long Term Incentive Plan 2026 to align employee incentives with company growth through performance stock units and restricted stock units. The 48th Annual General Meeting is scheduled for Thursday, August 06, 2026, and will be conducted via video conferencing.
Source: BSE
